{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-25-000047","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.427427+00:00","generated_at":"2026-05-17T01:30:32.099655+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biogen Q3 revenue $2.5B (+3% YoY); non-GAAP EPS $4.81 (+18%); FY25 guidance raised","bullets":["GAAP diluted EPS $3.17 (+19% YoY); Non-GAAP diluted EPS $4.81 (+18% YoY).","Launch products LEQEMBI ($121M, +82%), SKYCLARYS ($133M, +30%), ZURZUVAE ($55M) all show strong growth.","Full year 2025 revenue guidance raised to flat to +1% (constant currency); Non-GAAP EPS guided $14.50-$15.00.","Pipeline: LEQEMBI IQLIK approved, high-dose nusinersen resubmitted (PDUFA Apr'26), litifilimab Phase 3 fully enrolled (data H2'26)."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-25-000047","json":"https://secwatch.observer/filing/0000875045-25-000047.json","markdown":"https://secwatch.observer/filing/0000875045-25-000047.md","text":"https://secwatch.observer/filing/0000875045-25-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/0000875045-25-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/biib-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:30:32.099655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}